THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 106 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2020. The put-call ratio across all filers is 2.19 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $119,042 | -29.4% | 13,794 | -15.3% | 0.00% | – |
| Q2 2023 | $168,519 | -19.1% | 16,282 | -15.2% | 0.00% | – |
| Q1 2023 | $208,363 | -57.4% | 19,204 | -56.0% | 0.00% | -100.0% |
| Q4 2022 | $489,203 | -99.7% | 43,601 | +173.2% | 0.00% | – |
| Q3 2022 | $161,804,000 | -83.6% | 15,957 | -85.3% | 0.00% | -100.0% |
| Q2 2022 | $984,369,000 | -17.1% | 108,650 | -12.5% | 0.00% | 0.0% |
| Q1 2022 | $1,187,677,000 | +40.1% | 124,234 | +61.9% | 0.00% | +100.0% |
| Q4 2021 | $847,811,000 | +961.8% | 76,725 | +611.1% | 0.00% | – |
| Q3 2021 | $79,846,000 | +165.3% | 10,790 | +420.5% | 0.00% | – |
| Q2 2021 | $30,100,000 | -79.0% | 2,073 | -70.5% | 0.00% | – |
| Q1 2021 | $143,441,000 | -17.2% | 7,028 | -27.9% | 0.00% | – |
| Q4 2020 | $173,240,000 | +6.5% | 9,749 | -11.4% | 0.00% | – |
| Q3 2020 | $162,694,000 | +154.1% | 11,004 | +260.7% | 0.00% | – |
| Q2 2020 | $64,040,000 | -82.6% | 3,051 | -80.8% | 0.00% | -100.0% |
| Q1 2020 | $368,165,000 | +132.0% | 15,931 | +159.9% | 0.00% | – |
| Q4 2019 | $158,680,000 | +3.4% | 6,129 | -22.2% | 0.00% | – |
| Q3 2019 | $153,483,000 | +62.3% | 7,879 | +36.1% | 0.00% | – |
| Q2 2019 | $94,567,000 | -58.1% | 5,791 | -41.9% | 0.00% | – |
| Q1 2019 | $225,907,000 | +770.6% | 9,965 | +882.7% | 0.00% | – |
| Q4 2018 | $25,948,000 | -66.6% | 1,014 | -57.3% | 0.00% | – |
| Q3 2018 | $77,657,000 | +55.9% | 2,377 | +8.2% | 0.00% | – |
| Q2 2018 | $49,828,000 | -77.3% | 2,197 | -75.8% | 0.00% | – |
| Q1 2018 | $219,705,000 | -9.1% | 9,060 | +4.6% | 0.00% | – |
| Q4 2017 | $241,667,000 | +45.0% | 8,665 | +78.0% | 0.00% | – |
| Q3 2017 | $166,680,000 | -18.8% | 4,868 | -5.5% | 0.00% | -100.0% |
| Q2 2017 | $205,216,000 | +625.7% | 5,151 | +570.7% | 0.00% | – |
| Q1 2017 | $28,278,000 | -67.1% | 768 | -71.5% | 0.00% | – |
| Q4 2016 | $85,853,000 | -21.2% | 2,693 | -10.5% | 0.00% | – |
| Q3 2016 | $109,010,000 | +235.7% | 3,008 | +110.2% | 0.00% | – |
| Q2 2016 | $32,469,000 | -68.1% | 1,431 | -76.9% | 0.00% | – |
| Q4 2015 | $101,650,000 | +77.2% | 6,202 | +18.8% | 0.00% | – |
| Q3 2015 | $57,357,000 | +93.1% | 5,219 | +128.8% | 0.00% | – |
| Q2 2015 | $29,699,000 | +205.7% | 2,281 | +307.3% | 0.00% | – |
| Q1 2015 | $9,716,000 | -70.0% | 560 | -60.2% | 0.00% | – |
| Q3 2014 | $32,408,000 | – | 1,406 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,269,584 | $69,497,223,000 | 12.98% |
| Newtyn Management, LLC | 1,375,000 | $13,145,000 | 3.15% |
| Chescapmanager LLC | 1,166,574 | $11,152,000 | 1.51% |
| Baupost Group | 13,643,333 | $130,430,000 | 1.40% |
| Weiss Asset Management LP | 5,412,487 | $51,743,000 | 1.07% |
| CM Management, LLC | 120,000 | $1,147,000 | 0.96% |
| Orbimed Advisors | 3,254,713 | $31,115,000 | 0.50% |
| King Wealth Management Group | 122,000 | $1,166,000 | 0.23% |
| Woodline Partners LP | 1,326,653 | $12,683,000 | 0.21% |
| PDT Partners, LLC | 192,701 | $1,842,000 | 0.16% |